StockTipsArenaBeta

SELL Lupin Limited — ICICI Securities

SELLLupin Limited
Lupin share price target & all analyst calls

byICICI SecuritiesHorizon: NA (inferred 1 year)9 Aug 2026via Institutional / Brokerage Research

Entry₹2,360Inferred
Target₹2,200
Total upside +6.78% (call closed)
Stop lossNot given
Exit₹2,20021 Aug 2026, 12:08 pm
Target hit+6.78%0.00%upside left
Follow ICICI Securities for new calls(67% target hit, 1026 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 12 active Long-term calls on LUPINSee 214 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 21 Aug 2026
7 supporting2 neutral38 opposing
Supports the SELL call (7)

US tariff threat drags Nifty Pharma 1.3% lower at close; Lupin, PPL Pharma lead decline

NewsHbl·22 Jul · 4w ago

(opens in new tab)

US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline

NewsHbl·22 Jul · 4w ago

(opens in new tab)
Neutral / worth noting (2)

Lupin Q1 Review: Broad-Based Growth Impresses, But Systematix Sees US Competition Ahead — Check Target Price

NewsNdtv-Profit·10 Aug · 2w ago

(opens in new tab)
Weighs against the SELL call (38)

Lupin arm gets exclusive rights to presbyopia treatement drug in Europe

NewsCnbc-Tv18·20 Aug · today

(opens in new tab)

Lupin Ltd's wholly owned subsidiary, VISUfarma B.V., has entered into an Exclusive License Agreement with Visus Therapeutics, Inc.

BSE · Company Update·20 Aug · yesterday

(opens in new tab)

Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness

NewsEt-Markets·18 Aug · 3d ago

(opens in new tab)

Lupin Ltd has received approval from the U.S. FDA for its Pitolisant Tablets. This approval is a significant step for the company's pharmaceutical offerings.

BSE · Company Update·17 Aug · 3d ago

(opens in new tab)

Lupin Limited announced that the U.S. FDA has approved its Pitolisant Tablets. This approval is a significant step for the company's product portfolio.

NSE · Press Release·17 Aug · 3d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from ICICI Securities

Every call and its outcome